tetano
Editor, Senior Moderator
J Cardiol Cases
. 2022 Apr 26.
doi: 10.1016/j.jccase.2022.03.012. Online ahead of print.
A 17-year-old male with acute myocarditis following mRNA-1273 vaccination in Japan
Ayumi Iwamuro[SUP] 1 [/SUP], Tomoki Sasa[SUP] 1 [/SUP], Takafumi Kawai[SUP] 1 [/SUP], Mamoru Taguchi[SUP] 1 [/SUP], Masayasu Izuhara[SUP] 1 [/SUP], Takashi Uegaito[SUP] 1 [/SUP], Keisuke Shioji[SUP] 1 [/SUP]
Affiliations
Abstract
Vaccinations are the main tool being used to control the COVID-19 pandemic. When the Japanese Ministry of Health approved the Moderna mRNA-1273 vaccination in May 2021, it was limited to patients over 18 years old; however, using the additional data of efficacy and safety from clinical trials, vaccination was approved for 12- to 17-year-olds in Japan in July 2021. A previous study reported that myocarditis after the mRNA-1273 vaccination was more prevalent in young men; however, no patients under 18 years old with myocarditis diagnosed by cardiovascular magnetic resonance (CMR) findings after mRNA-1273 vaccination have been reported in Japan. In the present case, a 17-year-old healthy male developed arthralgia and had fever on the day of the second mRNA-1273 vaccination for severe acute respiratory syndrome coronavirus 2. Three days after the vaccination, the patient felt severe chest pain with broad ST elevations on electrocardiography and troponin T elevations. Symptoms and findings rapidly improved; however, on CMR, myocarditis remained. Thus, it is necessary to be vigilant of potential acute myocarditis in young men following mRNA-1273 vaccination.
Learning objective: Although it is very rare, acute myocarditis after mRNA-1273 (Moderna) vaccination developed within 3-5 days following the second dose of the vaccine.Most reported cases were mild or moderate in severity, but there were cases of cardiogenic shock. We need to be vigilant of acute myocarditis in young men following mRNA-1273 vaccination.
Keywords: CMR; Case report; Myocarditis; Vaccine; Young male; mRNA-1273.
. 2022 Apr 26.
doi: 10.1016/j.jccase.2022.03.012. Online ahead of print.
A 17-year-old male with acute myocarditis following mRNA-1273 vaccination in Japan
Ayumi Iwamuro[SUP] 1 [/SUP], Tomoki Sasa[SUP] 1 [/SUP], Takafumi Kawai[SUP] 1 [/SUP], Mamoru Taguchi[SUP] 1 [/SUP], Masayasu Izuhara[SUP] 1 [/SUP], Takashi Uegaito[SUP] 1 [/SUP], Keisuke Shioji[SUP] 1 [/SUP]
Affiliations
- PMID: 35495897
- PMCID: PMC9040371
- DOI: 10.1016/j.jccase.2022.03.012
Abstract
Vaccinations are the main tool being used to control the COVID-19 pandemic. When the Japanese Ministry of Health approved the Moderna mRNA-1273 vaccination in May 2021, it was limited to patients over 18 years old; however, using the additional data of efficacy and safety from clinical trials, vaccination was approved for 12- to 17-year-olds in Japan in July 2021. A previous study reported that myocarditis after the mRNA-1273 vaccination was more prevalent in young men; however, no patients under 18 years old with myocarditis diagnosed by cardiovascular magnetic resonance (CMR) findings after mRNA-1273 vaccination have been reported in Japan. In the present case, a 17-year-old healthy male developed arthralgia and had fever on the day of the second mRNA-1273 vaccination for severe acute respiratory syndrome coronavirus 2. Three days after the vaccination, the patient felt severe chest pain with broad ST elevations on electrocardiography and troponin T elevations. Symptoms and findings rapidly improved; however, on CMR, myocarditis remained. Thus, it is necessary to be vigilant of potential acute myocarditis in young men following mRNA-1273 vaccination.
Learning objective: Although it is very rare, acute myocarditis after mRNA-1273 (Moderna) vaccination developed within 3-5 days following the second dose of the vaccine.Most reported cases were mild or moderate in severity, but there were cases of cardiogenic shock. We need to be vigilant of acute myocarditis in young men following mRNA-1273 vaccination.
Keywords: CMR; Case report; Myocarditis; Vaccine; Young male; mRNA-1273.